Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

• Main Authors: Y. Wang, S. Thongsawat, E. J. Gane, Y. F. Liaw, J. Jia, J. Hou, H. L Y Chan, G. Papatheodoridis, M. Wan, J. Niu, W. Bao, A. Trylesinski, N. V. Naoumov
• 格式: 雜誌
• 出版: 2018
• 主題: Immunology and Microbiology; Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875229260&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/52645
• 機構: Chiang Mai University

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...